Researchers have developed engineered human microglia that detect disease-related brain changes and release therapeutic ...

CRISPR and CRISPR-Associated Gene Market Set to Surge to $20 Billion by 2035, Fueled by Technological Breakthroughs and Biotech Investments The global CRISPR and CRISPR-Associated Gene Market Size is ...

Fintel reports that on April 21, 2025, Wolfe Research upgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human ...

The North America CRISPR gene editing market is poised for substantial growth, with projections indicating a robust annual expansion of 24.4% throughout the forecast period. By 2031, it is anticipated ...

The CRISPR gene editing technology has revolutionized the field of molecular biology, offering unprecedented precision and efficiency in genetic manipulation. With its vast potential in various ...

A class action lawsuit was filed against Intellia Therapeutics Inc. (NTLA) by Levi & Korsinsky on February 11, 2025. The ...

AskBio Inc., a gene therapy company wholly owned and independently operated subsidiary of Bayer AG, has announced that its ...

NEW YORK, April 8, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30 ...

NEW YORK, April 8, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and ...

CRISPR MarketThe CRISPR Market had an estimated market share worth USD 3.4 billion in 2023, and it is predicted to reach a global market valuation of USD 17.8 billion by 2034, growing at a CAGR of 16.

NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA ) of a class action securities lawsuit.